Table 3.
Incidence of VTE in osteoporotic patients treated with strontium ranelate or alendronate sodium versus untreated osteoporotic patients
| Treated osteoporotic patients | Untreated osteoporotic patients (N = 11,546) | ||
|---|---|---|---|
| Strontium ranelate (N = 2,408) | Alendronate sodium (N = 20,084) | ||
| Patients with VTE (N) | 13 | 140 | 61 |
| Annual incidence (per 1,000 PY) | 7.0 | 7.2 | 5.6 |
| Adjusted model on agea | |||
| HR (SE) | 1.15 (0.31) | 1.10 (0.16) | |
| 95% CI | 0.63–2.10 | 0.81–1.50 | |
| p value | 0.656 | 0.530 | |
| Fully adjustedb | |||
| HR (SE) | 1.09 (0.31) | 0.92 (0.19) | |
| 95% CI | 0.60–2.01) | 0.63–1.33) | |
| p value | 0.773 | 0.646 | |
VTE venous thromboembolism (including deep venous thrombosis, pulmonary embolism, or retinal vein thrombosis, CI confidence interval, HR hazard ratio, SE standard error, PY patients–years
aHR between groups based on a Cox proportional hazards regression model adjusted on age
bHR between groups based on a Cox proportional hazards regression model fully adjusted for all confounders described in the Methods section (final regression model by backward selection)